Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vosoritide in infants and young children with hypochondroplasia
2024-512261-14-00Phase 2Authorised
- Sponsor
- BioMarin Pharmaceutical
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in hypochondroplasia (HCH) comparing Voxzogo with Placebo (2 arms). Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of serious adverse events and 3 more. Planned start Dec 2025; status: authorised.
02
Drugs
vosoritide
03
Conditions
hypochondroplasia (HCH)
Beyond the preview
Go deeper on 2024-512261-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512261-14-00.